Recently, it was demonstrated that profound levels of TAMs (M2 type) in lung cancer correlate with poor prognosis and survival rate of patients due to the augmented expression of vascular endothelial growth factors (VEGF), especially VEGF-A and VEGF-C [19,20]. The gene discussed is VEGFA; the disease is lung cancer.